Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer.
James, Roger D
Steward, William P
Barber, Philip V
Lawson, B A
Carroll, K B
AffiliationCancer Research Campaign Department of Medical Oncology; Department of Radiotherapy, Christie.
MetadataShow full item record
AbstractOne hundred eleven patients with inoperable but limited-stage small cell lung cancer were treated with three courses of cyclophosphamide (1.5, 2.5, and 3.5 g/m2, respectively) and VP-16-213 followed by methotrexate and thoracic radiotherapy. The total duration of treatment was 3 months. Patients were included who had pleural effusions, contralateral neck nodes, and bone marrow infiltration. The complete response (CR) rate was 56%, the majority confirmed by repeat bronchoscopy, with an 81% overall response rate. The minimum follow-up was 14 months. Median survival for all 111 patients was 11 months and 14 months (1-34+) for complete responders; the median survival was also 11 months for the 91 patients with conventional limited-stage disease, although 15 of the 19 patients alive at 14 months or more were from this subpopulation. There was no significant difference in the survival of those CR patients whose response was confirmed bronchoscopically and patients whose CR was assessed only radiologically and clinically. Forty-four patients with leukopenia (less than 1000 cells/microliter) received intravenous antibiotics for malaise and suspected infection. Close monitoring between treatments and direct access of patients to the hospital was encouraged. The majority of patients improved symptomatically as assessed by Karnofsky and Respiratory scores. These results support the view that short but intensive treatment without long-term or maintenance chemotherapy is beneficial.
CitationThree months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer. 1985, 56 (6):1332-6 Cancer
- Three months treatment with chemotherapy and radiotherapy for small cell lung cancer.
- Authors: Thatcher N, Stout R, Smith DB, Grötte G, Winson M, Bassett H, Carroll KB
- Issue date: 1985 Sep
- Short duration combination chemotherapy in the treatment of small cell lung cancer.
- Authors: Dorward AJ, Banham SW, Hutcheon AW, Ahmedzai S, Cunningham D, Gregor A, Soukop M, Stack BH, Mackay NS, Kaye SB
- Issue date: 1986 Sep
- Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
- Authors: Thomas CR Jr, Giroux DJ, Stelzer KJ, Craig JB, Laufman LR, Taylor SA, Goodwin JW, Crowley JJ, Livingston RB
- Issue date: 1998 Mar 15
- A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.
- Authors: Bleehen NM, Girling DJ, Machin D, Stephens RJ
- Issue date: 1993 Dec
- Long-term effects of intravenous hyperalimentation administered during intensive chemotherapy for small cell bronchogenic carcinoma.
- Authors: Valdivieso M, Frankmann C, Murphy WK, Benjamin RS, Barkley HT Jr, McMurtrey MJ, Jeffries DG, Welch SR, Bodey GP
- Issue date: 1987 Jan 15